BioLineRx Ltd.

(RTTNews) - (Amended: Withdraws and recasts the earlier story)
BioLineRx Ltd. (BLRX), a commercial-stage biopharmaceutical company, and Ayrmid Ltd., the parent company of Gamida Cell Ltd (GMDA), have entered into an exclusive license agreement to commercialize APHEXDA.
APHEXDA, developed by BioLineRx, is a hematopoietic stem cell mobilizer indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. The drug was launched last year.
As part of the agreement, Ayrmid has secured an exclusive license from BioLineRx to develop and commercialize APHEXDA across all indications, excluding solid tumor indications, and in all regions, other than Asia. The exclusive license for APHEXDA in the Asia region is held by Gloria Biosciences.
In turn, BioLineRx will receive a $10 million upfront payment and is also eligible to receive up to an additional $87 million of potential commercial milestones, along with royalties between 18% and 23% on net sales of APHEXDA.
As previously mentioned, BioLineRx retains the rights to develop and commercialize APHEXDA in solid tumors, including pancreatic ductal adenocarcinoma, and will continue its development for this indication through significant collaborations. APHEXDA will be added to Ayrmid's commercial portfolio, which already includes Gamida Cell's OMISIRGE, the first and only FDA-approved, nicotinamide (NAM)-modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx's U.S.-based commercial organization, who will support both stem cell transplant drugs.
Through this transaction, BioLineRx is expected to significantly reduce its long-term debt and operational expenses, the details of which will be discussed during the company's upcoming Q3 results conference call and webcast.
BioLineRx also revealed that it has received a $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support its pipeline and growth. The equity investment is expected to close today, subject to the fulfilment of customary closing conditions.
BLRX has traded in a range of $0.39 to $1.89 in the last 1 year. The stock closed yesterday's trading at $0.54, up 1.36%. In premarket trading today, BLRX is down over 24% to $0.41.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Amended: BioLineRx Inks License Agreement With Ayrmid To Commercialize Aphexda

The following companies are expected to report earnings prior to market open on 03/26/2024. Visit our Earnings Calendar for a full list of expected earnings releases.
Acumen Pharmaceuticals, Inc. (ABOS)is reporting for the quarter ending December 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.29. This value represents a 9.38% increase compared to the same quarter last year. ABOS missed the consensus earnings per share in the 4th calendar quarter of 2022 by -14.29%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ABOS is 0.00 vs. an industry ratio of -3.10, implying that they will have a higher earnings growth than their competitors in the same industry.
BioLineRx Ltd. (BLRX)is reporting for the quarter ending December 31, 2023. The drug company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.22. This value represents a 144.44% decrease compared to the same quarter last year. BLRX missed the consensus earnings per share in the 1st calendar quarter of 2023 by -7.14%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for BLRX is 0.00 vs. an industry ratio of -6.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Cognition Therapeutics, Inc. (CGTX)is reporting for the quarter ending December 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.38. This value represents a 90.00% decrease compared to the same quarter last year. CGTX missed the consensus earnings per share in the 1st calendar quarter of 2023 by -23.53%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CGTX is 0.00 vs. an industry ratio of -3.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Delcath Systems, Inc. (DCTH)is reporting for the quarter ending December 31, 2023. The medical instruments company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.67. This value represents a 22.09% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DCTH is 0.00 vs. an industry ratio of 4.40.
DouYu International Holdings Limited (DOYU)is reporting for the quarter ending December 31, 2023. The gaming company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.02. This value represents a 0.00% decrease compared to the same quarter last year. In the past year DOYU and beat the expectations the other quarter. The "days to cover" for this stock exceeds 24 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for DOYU is 0.00 vs. an industry ratio of 17.10.
Elbit Systems Ltd. (ESLT)is reporting for the quarter ending December 31, 2023. The aerospace and defense company's consensus earnings per share forecast from the 1 analyst that follows the stock is $1.38. This value represents a 17.86% decrease compared to the same quarter last year. The last two quarters ESLT had negative earnings surprises; the latest report they missed by -1.73%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ESLT is 0.00 vs. an industry ratio of 26.30.
GDS Holdings Limited (GDS)is reporting for the quarter ending December 31, 2023. The technology services company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.38. This value represents a 137.50% decrease compared to the same quarter last year. GDS missed the consensus earnings per share in the 1st calendar quarter of 2023 by -42.86%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for GDS is 0.00 vs. an industry ratio of -22.60, implying that they will have a higher earnings growth than their competitors in the same industry.
Terran Orbital Corporation (LLAP)is reporting for the quarter ending December 31, 2023. The wireless equipment company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.18. This value represents a 41.94% increase compared to the same quarter last year. The last two quarters LLAP had negative earnings surprises; the latest report they missed by -24%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for LLAP is 0.00 vs. an industry ratio of 8.80.
McCormick & Company, Incorporated (MKC)is reporting for the quarter ending February 29, 2024. The food company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.58. This value represents a 1.69% decrease compared to the same quarter last year. In the past year MKC and beat the expectations the other three quarters. Zacks Investment Research reports that the 2024 Price to Earnings ratio for MKC is 0.00 vs. an industry ratio of 51.40.
TD SYNNEX Corporation (SNX)is reporting for the quarter ending February 29, 2024. The electrical instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $2.71. This value represents a 3.90% decrease compared to the same quarter last year. SNX missed the consensus earnings per share in the 2nd calendar quarter of 2023 by -1.66%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for SNX is 0.00 vs. an industry ratio of 17.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-Market Earnings Report for March 26, 2024 : ABOS, BLRX, CGTX, DCTH, DOYU, ESLT, GDS, LLAP, MKC, SNX

(RTTNews) - BioLineRx Ltd. (BLRX) Thursday said the license agreement with Guangzhou Gloria Biosciences Co., Ltd. and an associated investor to develop Motixafortide across all indications in Asia has been concluded.
In September this year, the FDA approved Motixafortide for stem cell mobilization (SCM) in autologous stem cell transplantation (ASCT) in patients with multiple myeloma.
As per the deal, GloriaBio will be responsible for development and commercialization of motixafortide in Asia initially in SCM. GloriaBio is expected to initiate a bridging study to support potential approval of Motixafortide in the licensed territories in SCM for ASCT in patients with multiple myeloma.
The company also plans to begin Phase a 2/3 study to evaluate motixafortide in combination with zimberelimab and standard of care chemotherapy for the first-line treatment of pancreatic cancer.
The deal included an upfront payment of $15 million, up to $50 million in milestone payments, up to $200 million on achieving certain sales targets, and tiered double-digit royalties on sales. The transaction also included an equity investment of $14.6 million in BioLineRx.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.